Clinical trials
Primary Ovarian Insufficiency clinical trials
Below are recruiting primary ovarian insufficiency clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT07357701Recruiting
Genetic study for unexplained infertility in men and women
This study aims to find genetic causes of certain types of infertility in men and women. If you have been diagnosed with very low sperm count, no sperm, or early ovarian failure, researchers will look at your DNA to discover new genes that might be responsible.
Bethesda, MarylandAges 18–100 - NCT06339489Recruiting
Bone Health in Early Menopause Study
This study looks at how bone health changes in women with premature ovarian insufficiency (early menopause). It aims to understand the body's bone metabolism to help manage long-term health.
BeijingAges 18–39 - NCT05567198Recruiting
Testing hormone shots to protect ovaries during lupus chemotherapy
This study looks at whether a monthly/3-month hormone medicine (a “GnRH shot”) can help protect ovaries in people with lupus who are treated with cyclophosphamide. It also compares this to lupus patients who do not receive the ovarian-protecting shot, using questionnaires to track outcomes.
Bethesda, MarylandAges 18–120 - NCT06834594RecruitingPhase 4
Bleeding patterns in teens with Turner syndrome on progesterone
This study looks at how different ways of taking progesterone (a hormone given along with estrogen) affect bleeding patterns in teens with Turner syndrome. The goal is to find the best hormone schedule to cause regular, predictable periods.
Kansas City, MissouriAges 12–20 - NCT03989154Recruiting
Study for ovarian insufficiency in people under 40
This trial looks at treatment options for people under age 40 who have stopped having periods for at least four months and have lab results that suggest ovarian function is low. It may help improve symptoms or hormone balance for those who fit the hormone pattern.
Zhengzhou, HenanAges 18–40 - NCT05327283Recruiting
Genetic testing for early menopause in younger people
This study looks at DNA changes to understand the cause of premature ovarian insufficiency (early menopause). It may help clarify what’s happening in your body and guide future care.
GenovaAges 15–38 - NCT06167135Recruiting
PCOS, Insulin Resistance, and Fertility Study
This study looks at how polycystic ovary syndrome (PCOS) and insulin resistance (a condition where your body doesn't use insulin well) are linked to energy problems in cells (mitochondrial dysfunction). It aims to understand how these conditions affect fertility in women.
BudapestAges 20–45 - NCT06357442Recruiting
Comparing progesterone methods for young people on estrogen therapy
This study compares two ways to give progesterone to young people on estrogen replacement therapy to see how they affect the lining of the uterus. It will help find which approach may be safer and more effective for your health.
Aurora, ColoradoAges 12–25 - NCT06639074RecruitingPhase 2
Folate receptor dendritic cell vaccine for ovarian cancer
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
Scottsdale, ArizonaAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT02846064Recruiting
Ovarian tissue graft to restore ovarian function
This study looks at using your own frozen ovarian tissue that was saved earlier, then grafting it back to help restart normal ovarian function. It may be an option for people with premature ovarian failure who have been treated for their original cancer/illness.
BesançonAges 18–43 - NCT06096766Recruiting
Ovarian function and blood markers study
This study looks at how certain blood markers relate to ovarian function in women with normal ovaries, diminished ovarian reserve (DOR), or primary ovarian insufficiency (POI). It may help doctors better understand these conditions.
BeijingAges 18–45 - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT07775391RecruitingPhase 1/Phase 2
Stem cell infusion for early menopause
This trial tests whether a single infusion of stem cells made from human umbilical cord tissue can help women with premature ovarian insufficiency (early menopause) by improving ovarian function and reducing menopause symptoms. Participants will continue their usual hormone replacement therapy during the study.
Beijing, Beijing MunicipalityAges 18–40 - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT07495124RecruitingPhase 2
IGFBP-2 vaccine to prevent ovarian cancer return
This trial tests a vaccine that targets a protein called IGFBP-2 to prevent ovarian cancer from coming back. It is for people whose CA-125 blood test shows the cancer might be returning, but who don't yet have tumors visible on scans.
Seattle, WashingtonAges 18 years+ - NCT05460000RecruitingPhase 2
Niraparib after early ovarian cancer chemo—short vs long
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
InnsbruckAges 18 years+ - NCT03983226RecruitingPhase 2
Surgery plus niraparib for returning ovarian cancer
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07667192Recruiting
Re-treating gynecologic cancer with repeat radiation or ablation
This trial studies using additional radiation or tumor-destroying techniques for gynecologic cancer that has come back after previous radiation treatment. It helps doctors understand if this approach is safe and effective for women with recurrent disease.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT05737303RecruitingPhase 3
First-line chemotherapy comparison for advanced ovarian cancer
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
Guangzhou, GuangdongAges 18–75 - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+
Hear when a new Primary Ovarian Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary ovarian insufficiency?
- Yes. Clin2 currently lists 22 recruiting primary ovarian insufficiency studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary ovarian insufficiency trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary ovarian insufficiency trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.